复方苦参注射液联合化疗治疗非小细胞肺癌临床研究

Clinical Study of Compound Kushen Injection(复方苦参注射液)Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer

目的观察复方苦参注射液联合化疗治疗非小细胞肺癌的临床疗效。方法将全部98例非小细胞肺癌病例按照随机数字表法分为对照组和观察组各49例。对照组单纯采用TP化疗方案,予以紫杉醇和顺铂进行化疗。观察组在对照组的基础上加用复方苦参注射液治疗。治疗结束后观察比较两组临床疗效、疼痛缓解程度、免疫功能情况和不良反应。结果观察组临床总有效率(97.96%,48/49)明显高于对照组(73.47%,36/49)(P<0.05)。观察组疼痛总缓解率(97.96%,48/49)明显高于对照组(67.35%,33/49)(P<0.05)。治疗后观察组CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)明显高于对照组,CD_(8)^(+)明显低于对照组(P<0.05)。治疗后血清IL-6、IL-10、TNF-α水平观察组明显低于对照组(P<0.05)。观察组不良反应发生率明显低于对照组,P<0.05。结论复方苦参注射液联合化疗治疗晚期结肠癌可明显提高临床疗效,减轻患者的疼痛感,提高患者的免疫功能,降低化疗的不良反应。

Objective To observe the clinical efficacy of Compound Kushen Injection(复方苦参注射液)combined with chemotherapy in the treatment of non-small cell lung cancer.Methods All 98 cases of non-small cell lung cancer were randomly divided into control group and observation group with 49 cases in each group.The control group was treated with TP chemotherapy alone,paclitaxel and cisplatin.The observation group was treated with Compound Kushen Injection on the basis of the control group.After treatment,the clinical efficacy,pain relief,immune function and adverse reactions were observed and compared between the two groups.Results The total clinical effective rate of the observation group(97.96%,48/49)was significantly higher than that of the control group(73.47%,36/49)(P<0.05).The total pain relief rate of the observation group(97.96%,48/49)was significantly higher than that of the control group(67.35%,33/49)(P<0.05).After treatment,CD_(4)^(+)and CD_(4)^(+)/CD_(8)^(+)in the observation group were significantly higher than those in the control group,and CD_(8)^(+)was significantly lower than that in the control group(P<0.05).Serum levels of IL-6,IL-10 and TNF-α in the observation group were significantly lower than those in the control group after treatment(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group after treatment(P<0.05).Conclusion Compound Kushen Injection combined with chemotherapy in the treatment of advanced colon cancer can significantly improve the clinical efficacy,reduce the pain of patients,improve the immune function of patients,and reduce the adverse reactions of chemotherapy.